Literature DB >> 12871118

Combretastatin A-4 analogues as antimitotic antitumor agents.

Nguyen-Hai Nam1.   

Abstract

Tubulin protein is a major target for anticancer drug discovery. As a result, antimitotic agents constitute an important class of the current anticancer drugs. Hundreds of tubulin inhibitors, naturally occurring, semisynthetic or synthetic, have been reported. Among these, combretastatin A-4 (CA-4), isolated from a South African tree Combretum caffrum, is one of the most potent antimitotic agents. CA-4 shows strong cytotoxicity against a variety of cancer cells, including multi-drug resistant cancer cell lines. It has also been demonstrated to exert highly selective effects in proliferating endothelial cells. CA-4 disodium phosphate (CA4DP), a water-soluble prodrug of CA-4, shows potent antivascular and antitumor effects in a wide variety of preclinical tumor models. Consequently, a number of CA-4 analogues has been synthesized and evaluated. In this paper, the structure-activity relationships and pharmacological properties of the CA-4 derivatives as a class of potent antimitotic anticancer agents are reviewed and discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871118     DOI: 10.2174/0929867033457151

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  42 in total

1.  Synthesis and antitumor activity of 1,5-disubstituted 1,2,4-triazoles as cis-restricted combretastatin analogues.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Olga Cruz-Lopez; Carlota Lopez Cara; Maria Dora Carrion; Andrea Brancale; Ernest Hamel; Longchuan Chen; Roberta Bortolozzi; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

2.  Molecular modeling study, synthesis and biological evaluation of combretastatin A-4 analogues as anticancer agents and tubulin inhibitors.

Authors:  Yang Ping Quan; Li Ping Cheng; Tian Chi Wang; Wan Pang; Fan Hong Wu; Jin Wen Huang
Journal:  Medchemcomm       Date:  2017-12-06       Impact factor: 3.597

Review 3.  Recent advances in combretastatin based derivatives and prodrugs as antimitotic agents.

Authors:  Zaki S Seddigi; M Shaheer Malik; A Prasanth Saraswati; Saleh A Ahmed; Ahmed O Babalghith; Hawazen A Lamfon; Ahmed Kamal
Journal:  Medchemcomm       Date:  2017-07-04       Impact factor: 3.597

4.  Structural Optimization of Indole Derivatives Acting at Colchicine Binding Site as Potential Anticancer Agents.

Authors:  Dong-Jin Hwang; Jin Wang; Wei Li; Duane D Miller
Journal:  ACS Med Chem Lett       Date:  2015-08-06       Impact factor: 4.345

5.  Highly potent triazole-based tubulin polymerization inhibitors.

Authors:  Qiang Zhang; Youyi Peng; Xin I Wang; Susan M Keenan; Sonia Arora; William J Welsh
Journal:  J Med Chem       Date:  2007-01-24       Impact factor: 7.446

6.  Convergent synthesis and biological evaluation of 2-amino-4-(3',4',5'-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents.

Authors:  Romeo Romagnoli; Pier Giovanni Baraldi; Andrea Brancale; Antonio Ricci; Ernest Hamel; Roberta Bortolozzi; Giuseppe Basso; Giampietro Viola
Journal:  J Med Chem       Date:  2011-06-27       Impact factor: 7.446

7.  Tubulin inhibitors: pharmacophore modeling, virtual screening and molecular docking.

Authors:  Miao-Miao Niu; Jing-Yi Qin; Cai-Ping Tian; Xia-Fei Yan; Feng-Gong Dong; Zheng-Qi Cheng; Guissi Fida; Man Yang; Hai-Yan Chen; Yue-Qing Gu
Journal:  Acta Pharmacol Sin       Date:  2014-06-09       Impact factor: 6.150

8.  Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4.

Authors:  Nikhil R Madadi; Narsimha R Penthala; Kevin Howk; Amit Ketkar; Robert L Eoff; Michael J Borrelli; Peter A Crooks
Journal:  Eur J Med Chem       Date:  2015-08-29       Impact factor: 6.514

9.  A novel AMPK activator reduces glucose uptake and inhibits tumor progression in a mouse xenograft model of colorectal cancer.

Authors:  Silvia Valtorta; Gabriella Nicolini; Farida Tripodi; Cristina Meregalli; Guido Cavaletti; Federica Avezza; Luca Crippa; Gloria Bertoli; Francesca Sanvito; Paola Fusi; Roberto Pagliarin; Fulvia Orsini; Rosa Maria Moresco; Paola Coccetti
Journal:  Invest New Drugs       Date:  2014-08-19       Impact factor: 3.850

Review 10.  1,5-diaryl-3-oxo-1,4-pentadienes: a case for antineoplastics with multiple targets.

Authors:  U Das; R K Sharma; J R Dimmock
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.